Compare POWW & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POWW | EDIT |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 210.8M | 202.1M |
| IPO Year | N/A | 2016 |
| Metric | POWW | EDIT |
|---|---|---|
| Price | $1.73 | $2.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $2.38 | ★ $4.50 |
| AVG Volume (30 Days) | 364.4K | ★ 1.9M |
| Earning Date | 02-09-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $46,632,638.00 | $46,383,000.00 |
| Revenue This Year | $9.85 | N/A |
| Revenue Next Year | $1.88 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1343.57 | N/A |
| 52 Week Low | $1.08 | $0.91 |
| 52 Week High | $2.14 | $4.54 |
| Indicator | POWW | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 42.09 | 38.96 |
| Support Level | $1.78 | $1.99 |
| Resistance Level | $1.97 | $2.28 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 22.22 | 27.90 |
Outdoor Holding Co Formerly AMMO Inc is the owner of GunBroker.com, the online marketplace serving the firearms and shooting sports industries, and a vertically integrated producer of high-performance ammunition and components. It engages in the design, manufacture, and market of ammunition products in the Shooting sports industry in the United States. The firm's product segment comprises Ammunition and Marketplace. The Ammunition segment engages in the design, production, and marketing of ammunition and ammunition component products and the marketplace segment consists of the GunBroker.com marketplace. The company generates the majority of its revenue from the Ammunition segment.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.